Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2026 11:00 ET | Source: Institute of Molecular and Clinical Ophthalmology Basel (IOB)

What if you could reboot sick cells?

Researchers at IOB developed targeted delivery of healthy mitochondria to diseased cells, opening new paths for treating mitochondrial disorders.
April 08, 2026 14:53 ET | Source: Ernst Law Group

Taylor Ernst of the Ernst Law Group Publishes “The Bible of TBI”

Trial attorney Taylor Ernst publishes The Ernst Way, the first complete methodology for litigating traumatic brain injury cases (Ernst Media, 2025).
April 01, 2026 08:30 ET | Source: Actinogen Medical

Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update

SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial...
March 20, 2026 10:48 ET | Source: Longeviti Neuro Solutions

Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors

T. Rowe Price CEO Robert Sharps joins Longeviti Neuro Solutions board, signaling growth as the company scales its AI-enabled neurotechnology platform.
March 04, 2026 07:45 ET | Source: Firefly Neuroscience, Inc.

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new...
February 27, 2026 09:00 ET | Source: Novartis Pharma AG

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks...
February 17, 2026 03:30 ET | Source: FundaMental Pharma GmbH

FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference

FundaMental Pharma chosen among twelve companies to showcase its groundbreaking TRD candidate, FMP374, at the Bio-Neuroscience Conference.
February 11, 2026 08:00 ET | Source: Denovo Biopharma

Denovo Biopharma Announces Partnership with Orygen on Phase 2 Study Evaluating DB103 (Pomaglumetad Methionil) in Treating Psychosis

Denovo Biopharma Announces Partnership with Orygen on Phase 2 Study Evaluating DB103 (Pomaglumetad Methionil) in Treating Psychosis
February 02, 2026 08:00 ET | Source: Actinogen Medical

Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial

SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has...
January 27, 2026 12:30 ET | Source: Custom Market Insights

[Latest] Global Spatial Biology Market Size/Share Worth USD 7.24 Billion by 2035 at a 19.23% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Spatial Biology Market Size, Trends and Insights By Molecular Technology...